Disclosures: Kirk Bonner, MD: No financial relationships or conflicts of interest

Objective: To evaluate symptomatic improvement in patients with lumbar disc herniation who received lumbar percutaneous needle discectomy followed by intradiscal bone marrow derived mesenchymal stem cell (BM-MSC) injection.

Design: 6 patients with symptomatic lumbar disc herniation confirmed by MRI refractory to transforaminal epidural steroid injection underwent percutaneous needle discectomy followed by intradiscal injection of 1cc of BM-MSC from the PSIS. Patients reported pre-procedure pain level and post procedure percent improvement and pain level at various intervals up to 24 weeks. Setting : Outpatient Sports Medicine Clinic Participants : 6 adult patients with symptomatic MRI confirmed lumbar disc herniation refractory to transforaminal epidural steroid injection.

Interventions: Percutaneous needle discectomy followed by intradiscal bone marrow derived mesenchymal stem cell (BM-MSC) injection.

Main Outcome Measures: Subjectively reported functional improvement at 2, 4, 6, and 24 weeks following the procedure and post procedural pain level at 8 and 24 weeks.

Results: Patients reported an average improvement of 26.7% (0%-70%) after 2 weeks, 65% (50%-80%) after 4 weeks, 84.2% (75%-100%) after 6 weeks, and 84.2% (75%-100%) after 24 weeks. Average pain level improved from 8.2 (6-10) pre-procedure to 2 (1-3) and 1.3 (1-3) 8 and 24 weeks post-procedure, respectively. Conclusions: In a small cohort of 6 patients with symptomatic lumbar disc herniation, subjective reports of percent improvement and pain suggest that percutaneous needle discectomy followed by intradiscal BM-MSC injection is comparable to traditional discectomy.

Level of Evidence: Level IV

« Back to AAPM&R Annual Assembly 2020

PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/a-review-of-symptomatic-improvement-in-patients-following-percutaneous-needle-discectomy-and-intradiscal-stem-cell-injection/